Since 2002, CHAI has worked to increase access to HIV drugs and diagnostics in the developing world with the transformational goal of saving lives.
Through collaboration with a broad coalition of partners, the Interagency Task Team on the Prevention and Treatment of HIV infection in Pregnant Women, Mothers, and Children (IATT) has helped support the translation of technical support into country action.
As co-chair of the IATT’s Finance and Economics Working Group, CHAI played a key role in supporting countries with the costing of their five-year operational plans to scale-up their national programs with the goal of achieving virtual elimination of mother-to-child transmission (eMTCT) by 2015. A team from Zambia used these models to develop a plan to hasten the roll-out of treatment for all pregnant and breastfeeding women, regardless of CD4 count, and to expand eligibility to antiretroviral treatment to all children under the age of 15. Read more here.
Through the IATT Child Survival Working Group, CHAI supported the development of the IATT Optimal Formulary and Limited-use List, which includes the minimum number of antiretroviral (ARV) formulations needed to provide all currently recommended World Health Organization (WHO) preferred first- and second-line regimens for all pediatric weight bands. The list provides guidance to programs, donors, and manufacturers in selection of pediatric ARV dosage forms, thereby consolidating the market around a select number of optimal pediatric products. Read the IATT Pediatric ARV Formulary and Limited-use List here. CHAI’s work on the IATT Optimal Formulary was made possible through the generous support of UNITAID.
